Luke, J. J., Chmura, S. J., Allred, J. B., Salama, J. K., Al-Hallaq, H. A., Hsu, C., … Schwartz, G. K. (2018). A randomized phase II study of anti-PD1 antibody [MK-3475 (Pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605). In Journal of Clinical Oncology (Vol. 36, pp. TPS9599–TPS9599). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.tps9599

Luke, Jason J., Steven J. Chmura, Jacob B. Allred, Joseph Kamel Salama, Hania A. Al-Hallaq, Charles Hsu, Sue S. Yom, Mark Kozloff, Pamela N. Munster, and Gary K. Schwartz. “A randomized phase II study of anti-PD1 antibody [MK-3475 (Pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605).” In Journal of Clinical Oncology, 36:TPS9599–TPS9599. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps9599.

Luke JJ, Chmura SJ, Allred JB, Salama JK, Al-Hallaq HA, Hsu C, et al. A randomized phase II study of anti-PD1 antibody [MK-3475 (Pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS9599–TPS9599.

Luke, Jason J., et al. “A randomized phase II study of anti-PD1 antibody [MK-3475 (Pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605).” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. TPS9599–TPS9599. Crossref, doi:10.1200/jco.2018.36.15_suppl.tps9599.

Luke JJ, Chmura SJ, Allred JB, Salama JK, Al-Hallaq HA, Hsu C, Yom SS, Kozloff M, Munster PN, Schwartz GK. A randomized phase II study of anti-PD1 antibody [MK-3475 (Pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS9599–TPS9599.